2024 Targeted Therapies for Lung Cancer (TTLC) - Abstracts & Posters-PP01.21 Parang

PP01.21 Parang - Poster

Pdf Summary

The study by Parang et al. from Meyer Cancer Center explores the dysregulation of propionate metabolism leading to osimertinib resistance in lung cancer. They found that methylmalonic acid (MMA), a by-product of propionate metabolism, is elevated in non-small cell lung cancer (NSCLC) patients, both in tumors and plasma of metastatic patients. The key regulatory gene MMAB is underexpressed in NSCLC, particularly in adenocarcinomas, and correlates with overall survival in non-smokers. Knockdown of MMAB promotes osimertinib resistance, while overexpression enhances sensitivity to the drug. The study suggests that propionate metabolism dysregulation drives osimertinib resistance in NSCLC. The research highlights the importance of understanding MMA regulation and MMAB expression in lung cancer patients to potentially address osimertinib resistance. This study sheds light on a novel mechanism that could impact treatment strategies for NSCLC patients in the future.

Keywords

propionate metabolism

osimertinib resistance

lung cancer

methylmalonic acid

MMAB gene

non-small cell lung cancer

adenocarcinomas

overall survival

drug sensitivity

treatment strategies